SCHEMBL6415070

SCHEMBL6415070

CC(C)(C)NC(=O)c1ncccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
ANO1 Q5XXA6 4/20 0.45
ALDH1A1 P00352 3/20 0.43
HTT P42858 1/20 0.43
RIPK1 Q13546 1/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 2/20 0.42
TRPV1 Q8NER1 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.41
APEX1 P27695 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605525 0.81 SMN1; SMN2 (0.48) SMN1; SMN2ANO1ALDH1A1RIPK1KMT2A
SCHEMBL30853475 0.81 SMN1; SMN2 (0.48) SMN1; SMN2ANO1ALDH1A1RIPK1KMT2A
SCHEMBL1507135 0.81 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1HTTTSHRGAA
SCHEMBL22832228 0.80 SMN1; SMN2 (0.47) SMN1; SMN2ANO1ALDH1A1RIPK1TSHR
SCHEMBL6417499 0.80 ANO1 (0.47) SMN1; SMN2ANO1RIPK1TSHRTRPV1
SCHEMBL30131499 0.80 EGLN2 (0.43) ALDH1A1MEN1KMT2ATRPV1GAA
Hydrochloric Acid SCHEMBL28079784 0.79 NPC1 (0.46) SMN1; SMN2ALDH1A1HTTGAANPC1
SCHEMBL16240426 0.79 CNR1 (0.43) ANO1RIPK1POLBAPEX1CNR1
SCHEMBL24198697 0.77 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1HTTTSHRTRPV1
SCHEMBL22795757 0.77 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1HTTTSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP claimed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US claimed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP claimed
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1184367-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-03-06 EP disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed
EP-0187284-A2 Process for the preparation of N-tert. alkyl amides of pyridine-carboxylic acids BAYER AG (DE) 1986-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 SMN1; SMN2 2026/4885ANO1 3084/4885ALDH1A1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.